Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.03
RAD's Cash-to-Debt is ranked lower than
96% of the 372 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.51 vs. RAD: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
RAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.03 Max: 0.27
Current: 0.03
0
0.27
Equity-to-Asset 0.06
RAD's Equity-to-Asset is ranked lower than
97% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. RAD: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
RAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.38  Med: 0.01 Max: 0.39
Current: 0.06
-0.38
0.39
Interest Coverage 1.31
RAD's Interest Coverage is ranked lower than
94% of the 349 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.23 vs. RAD: 1.31 )
Ranked among companies with meaningful Interest Coverage only.
RAD' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 1.09 Max: 2.11
Current: 1.31
0.02
2.11
Piotroski F-Score: 5
Altman Z-Score: 2.86
Beneish M-Score: -2.51
WACC vs ROIC
18.23%
6.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.69
RAD's Operating Margin % is ranked lower than
66% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.87 vs. RAD: 1.69 )
Ranked among companies with meaningful Operating Margin % only.
RAD' s Operating Margin % Range Over the Past 10 Years
Min: -7.81  Med: 1.29 Max: 3.16
Current: 1.69
-7.81
3.16
Net Margin % 0.28
RAD's Net Margin % is ranked lower than
79% of the 374 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.77 vs. RAD: 0.28 )
Ranked among companies with meaningful Net Margin % only.
RAD' s Net Margin % Range Over the Past 10 Years
Min: -11.09  Med: -0.63 Max: 7.95
Current: 0.28
-11.09
7.95
ROE % 15.46
RAD's ROE % is ranked higher than
75% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.83 vs. RAD: 15.46 )
Ranked among companies with meaningful ROE % only.
RAD' s ROE % Range Over the Past 10 Years
Min: -1148.43  Med: -33.1 Max: 51.83
Current: 15.46
-1148.43
51.83
ROA % 0.79
RAD's ROA % is ranked lower than
76% of the 376 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.42 vs. RAD: 0.79 )
Ranked among companies with meaningful ROA % only.
RAD' s ROA % Range Over the Past 10 Years
Min: -29.43  Med: -2.28 Max: 26.83
Current: 0.79
-29.43
26.83
ROC (Joel Greenblatt) % 14.13
RAD's ROC (Joel Greenblatt) % is ranked lower than
52% of the 375 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.53 vs. RAD: 14.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -44.02  Med: 7.1 Max: 22.13
Current: 14.13
-44.02
22.13
3-Year Revenue Growth Rate 1.80
RAD's 3-Year Revenue Growth Rate is ranked lower than
65% of the 319 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. RAD: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16  Med: -3 Max: 11
Current: 1.8
-16
11
3-Year EBITDA Growth Rate 4.70
RAD's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 287 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.20 vs. RAD: 4.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: -1.9 Max: 24.2
Current: 4.7
-15.6
24.2
3-Year EPS without NRI Growth Rate 10.10
RAD's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 258 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.80 vs. RAD: 10.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.9  Med: 1.3 Max: 479.9
Current: 10.1
-59.9
479.9
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RAD's 10-Y Financials

Financials (Next Earnings Date: 2017-04-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RAD Guru Trades in Q1 2016

Jim Simons 94,200 sh (New)
Paul Tudor Jones 100,600 sh (New)
John Paulson 263,500 sh (New)
Mario Gabelli 1,067,250 sh (+48.77%)
Paul Tudor Jones 100,100 sh (unchged)
Eric Mindich Sold Out
Jeremy Grantham Sold Out
First Eagle Investment Sold Out
Ken Fisher Sold Out
Pioneer Investments 921,305 sh (-0.09%)
George Soros 500,000 sh (-38.17%)
Joel Greenblatt 71,752 sh (-57.17%)
» More
Q2 2016

RAD Guru Trades in Q2 2016

Leucadia National 857,991 sh (New)
Jeremy Grantham 2,382,600 sh (New)
John Burbank 14,678 sh (New)
David Einhorn 10,330,000 sh (New)
Jim Simons 5,295,600 sh (+5521.66%)
John Paulson 580,900 sh (+120.46%)
Mario Gabelli 1,385,875 sh (+29.85%)
Paul Tudor Jones 122,800 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Pioneer Investments 919,826 sh (-0.16%)
Paul Tudor Jones 83,605 sh (-16.89%)
» More
Q3 2016

RAD Guru Trades in Q3 2016

Eric Mindich 3,078,000 sh (New)
Paul Singer 3,179,854 sh (New)
Jeremy Grantham 3,889,139 sh (+63.23%)
Pioneer Investments 1,326,427 sh (+44.20%)
Leucadia National 1,208,291 sh (+40.83%)
David Einhorn 13,443,035 sh (+30.14%)
Paul Singer 2,000,000 sh (unchged)
Paul Tudor Jones 122,800 sh (unchged)
Jim Simons Sold Out
John Paulson Sold Out
John Burbank Sold Out
Mario Gabelli 1,369,975 sh (-1.15%)
Paul Tudor Jones 52,162 sh (-37.61%)
» More
Q4 2016

RAD Guru Trades in Q4 2016

First Pacific Advisors 169,000 sh (New)
David Einhorn 20,462,962 sh (+52.22%)
Paul Tudor Jones 122,800 sh (unchged)
Paul Tudor Jones Sold Out
Eric Mindich Sold Out
Paul Singer Sold Out
Leucadia National Sold Out
Pioneer Investments 1,294,187 sh (-2.43%)
Mario Gabelli 1,191,650 sh (-13.02%)
Jeremy Grantham 2,047,600 sh (-47.35%)
» More
» Details

Insider Trades

Latest Guru Trades with RAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Rite Aid Corp

SymbolPriceYieldDescription
RADCO0.000.00Conv Pfd Shs Series -I-

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:OTCPK:RADLY, OTCPK:JCOUF, OTCPK:CLCGY, NYSE:GNC, NAS:PETS, OTCBB:COCP, NAS:CJJD, OTCPK:HEWA, OTCPK:ASDS, NAS:WBA » details
Traded in other countries:RTA.Germany,
Rite Aid Corp operates retail drugstore chains in the United States. As of February 28, 2015, the Company operated 4,570 stores in 31 states across the country and in the District of Columbia.

Rite Aid Corp a Delaware corporation was incorporated in 1968. It operates retail drugstore chain in the United States. The Company operated approximately 4,561 stores in 31 states across the country and in the District of Columbia. Its segments include Retail Pharmacy Segment and New Pharmacy Segment. The Company sells prescription drugs and an assortment of other merchandise, which it calls 'front end' products. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise and numerous other convenience products. The Company attempts to distinguish its stores from other national chain drugstores, in part, through its wellness + loyalty program, private brands and its strategic alliance with GNC, a retailer of vitamin and mineral supplements. The retail drugstore industry is competitive. It competes with retail drugstore chains, independently owned drugstores, supermarkets, mass merchandisers, discount stores, wellness offerings, dollar stores and mail order pharmacies. The Company's business is subject to federal, state, and local government laws, regulations and administrative practices.

Top Ranked Articles about Rite Aid Corp

Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Deal’s value reduced by at least $2 billion
Walgreens Boots Alliance (NASDAQ:WBA) and Rite Aid Corp. (NYSE:RAD) announced on Monday they are reducing the price and postponing the close of their definitive merger agreement. Read more...
David Einhorn Adds Calpine, Rite Aid, Amaya to Portfolio The guru’s top 3 new holdings
David Einhorn (Trades, Portfolio) of Greenlight Capital acquired three new holdings during the second quarter. They are Calpine Corp. (NYSE:CPN), Rite Aid Corp. (NYSE:RAD) and Amaya Inc. (NASDAQ:AYA). Read more...

Ratios

vs
industry
vs
history
PE Ratio 74.63
RAD's PE Ratio is ranked lower than
93% of the 329 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. RAD: 74.63 )
Ranked among companies with meaningful PE Ratio only.
RAD' s PE Ratio Range Over the Past 10 Years
Min: 1.91  Med: 16.74 Max: 328.5
Current: 74.63
1.91
328.5
PE Ratio without NRI 74.63
RAD's PE Ratio without NRI is ranked lower than
92% of the 310 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.92 vs. RAD: 74.63 )
Ranked among companies with meaningful PE Ratio without NRI only.
RAD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.91  Med: 16.74 Max: 219
Current: 74.63
1.91
219
PB Ratio 9.68
RAD's PB Ratio is ranked lower than
96% of the 387 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.86 vs. RAD: 9.68 )
Ranked among companies with meaningful PB Ratio only.
RAD' s PB Ratio Range Over the Past 10 Years
Min: 0.29  Med: 2.67 Max: 151.55
Current: 9.68
0.29
151.55
PS Ratio 0.19
RAD's PS Ratio is ranked higher than
80% of the 384 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. RAD: 0.19 )
Ranked among companies with meaningful PS Ratio only.
RAD' s PS Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.1 Max: 0.34
Current: 0.19
0.01
0.34
Price-to-Operating-Cash-Flow 12.62
RAD's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 219 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.00 vs. RAD: 12.62 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RAD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.52  Med: 8.07 Max: 84.58
Current: 12.62
0.52
84.58
EV-to-EBIT 24.54
RAD's EV-to-EBIT is ranked lower than
78% of the 337 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.14 vs. RAD: 24.54 )
Ranked among companies with meaningful EV-to-EBIT only.
RAD' s EV-to-EBIT Range Over the Past 10 Years
Min: -2331.6  Med: 21.15 Max: 3760.7
Current: 24.54
-2331.6
3760.7
EV-to-EBITDA 12.09
RAD's EV-to-EBITDA is ranked higher than
52% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 12.24 vs. RAD: 12.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
RAD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.2  Med: 12.35 Max: 17.3
Current: 12.09
-6.2
17.3
PEG Ratio 4.55
RAD's PEG Ratio is ranked lower than
73% of the 164 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.16 vs. RAD: 4.55 )
Ranked among companies with meaningful PEG Ratio only.
RAD' s PEG Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2.6 Max: 9.23
Current: 4.55
0.16
9.23
Current Ratio 1.63
RAD's Current Ratio is ranked higher than
69% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.21 vs. RAD: 1.63 )
Ranked among companies with meaningful Current Ratio only.
RAD' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.8 Max: 2.42
Current: 1.63
0.81
2.42
Quick Ratio 0.67
RAD's Quick Ratio is ranked lower than
55% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.74 vs. RAD: 0.67 )
Ranked among companies with meaningful Quick Ratio only.
RAD' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.46 Max: 1.25
Current: 0.67
0.13
1.25
Days Inventory 41.07
RAD's Days Inventory is ranked lower than
52% of the 363 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.30 vs. RAD: 41.07 )
Ranked among companies with meaningful Days Inventory only.
RAD' s Days Inventory Range Over the Past 10 Years
Min: 41.07  Med: 63.29 Max: 70.58
Current: 41.07
41.07
70.58
Days Sales Outstanding 19.13
RAD's Days Sales Outstanding is ranked lower than
56% of the 273 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.31 vs. RAD: 19.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
RAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.31  Med: 13.54 Max: 19.13
Current: 19.13
7.31
19.13
Days Payable 26.35
RAD's Days Payable is ranked lower than
78% of the 267 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 47.86 vs. RAD: 26.35 )
Ranked among companies with meaningful Days Payable only.
RAD' s Days Payable Range Over the Past 10 Years
Min: 21.83  Med: 25.85 Max: 29.42
Current: 26.35
21.83
29.42

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
RAD's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 198 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.60 vs. RAD: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.8  Med: -3.7 Max: -0.3
Current: -4.9
-25.8
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.23
RAD's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
80% of the 215 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.53 vs. RAD: 3.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RAD' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.35  Med: 3.58 Max: 10.26
Current: 3.23
1.35
10.26
Price-to-Median-PS-Value 1.93
RAD's Price-to-Median-PS-Value is ranked lower than
91% of the 341 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.11 vs. RAD: 1.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.34 Max: 8.98
Current: 1.93
0.09
8.98
Price-to-Peter-Lynch-Fair-Value 6.35
RAD's Price-to-Peter-Lynch-Fair-Value is ranked lower than
98% of the 91 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.63 vs. RAD: 6.35 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
RAD' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.16  Med: 1.74 Max: 8.47
Current: 6.35
0.16
8.47
Earnings Yield (Greenblatt) % 4.06
RAD's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 403 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.80 vs. RAD: 4.06 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 4.4 Max: 8.2
Current: 4.06
0.3
8.2
Forward Rate of Return (Yacktman) % 15.07
RAD's Forward Rate of Return (Yacktman) % is ranked higher than
75% of the 230 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.38 vs. RAD: 15.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RAD' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -33.7  Med: 0.8 Max: 56.7
Current: 15.07
-33.7
56.7

More Statistics

Revenue (TTM) (Mil) $32,574
EPS (TTM) $ 0.08
Beta1.89
Short Percentage of Float2.74%
52-Week Range $5.20 - 8.77
Shares Outstanding (Mil)1,052.37

Analyst Estimate

Feb17
Revenue (Mil $)
EPS ($) 0.12
EPS without NRI ($) 0.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RAD

Headlines

Articles On GuruFocus.com
David Einhorn Buys Buffett’s Monsanto, Retail, Apple in Q4 Feb 15 2017 
Walgreens, Rite Aid Reduce Price, Postpone Closing of Merger Jan 30 2017 
Dividend Aristocrats in Focus Part 38: Walgreens Boots Alliance Nov 10 2016 
Why I Am Now Interested in CVS Health Corporation Oct 13 2016 
Rite Aid Is a Solid Risk Arbitrage Trade Sep 27 2016 
Why Walgreens Is a Long-Term Buy Now Sep 09 2016 
David Einhorn Adds Calpine, Rite Aid, Amaya to Portfolio Aug 16 2016 
CVS and Walgreens: A Duopoly That's Hard to Ignore Jul 08 2016 
In Spite of Less Revenue Rite Aid Still Has Growth Potential Jun 21 2016 
Walgreens Boots Alliance: 40 Consecutive Years of Dividend Growth and Counting Jun 17 2016 

More From Other Websites
What's working: Health and housing plays Feb 21 2017
At Long Last Walgreens and Rite Aid May Soon Be One Company Feb 16 2017
Einhorn Takes Fred's Stake Amid Deal Review Feb 16 2017
3 Stocks to Buy for Under $10 With 25%-Plus Upside Feb 16 2017
David Einhorn Buys Buffett's Monsanto, Retail, Apple in Q4 Feb 15 2017
Rite Aid Expands Naloxone Dispensing Program in Six Additional States Feb 15 2017
Greenlight Capital Bets on General Motors, Rite Aid Feb 14 2017
Wall Street's M&A Chatter From February 10-12 Feb 13 2017
Buy Rite Aid Because It's Very Likely to Be Owned by Walgreens Soon Feb 10 2017
CVS Health Earnings Growth Tops, But Sales Miss Estimates Feb 09 2017
Nvidia, Twitter, Yum, CVS, Expedia Lead Investing Action Plan Feb 08 2017
Implied Volatility Surging for Rite Aid (RAD) Stock Options Feb 06 2017
Rite Aid, Pitney Bowes Welcomed to Wednesday’s 52-Week Low Club Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)